ClinicalTrials.gg
Sign In
Not yet recruitingNCT07696858Updated Jul 10, 2026

Short-Term Tocolysis in Preterm Labor

An observational study in Preterm Labor, sponsored by Sohag University. Not yet recruiting. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-07-10.

Sponsored by Sohag University · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

The aim of this study is to identify independent prognostic factors associated with the success of short-term tocolysis, defined as delivery delayed by at least 48 hours, in women with singleton preterm labor

Read the detailed description

All participants will receive short-term tocolytic therapy according to the unit protocol.

  • The choice of tocolytic agent (., Magnesium sulphate ) will be determined by the treating physician.
  • Tocolysis will be administered for a maximum duration of 48-72 hours.
  • Antenatal corticosteroids (Betamethasone amp 12mg once daily for 2days) will be administered to eligible participants to enhance fetal lung maturity.
  • Failure documented when there is efficient uterine contractions more 4/10mins each one lasts more than 40 seconds, and there was progressive cervical dilatation more 3cm
02

Conditions studied

  • Preterm Labor

Keywords

  • tocolysis
  • preterm labor
03

In context

Obstetric Labor, Premature

242 studies on the registry are indexed under Obstetric Labor, Premature; 36 are open to participants now.

This study's planned enrollment of 100 is below the median of 125 across 81 observational studies indexed under Obstetric Labor, Premature.

Browse Obstetric Labor, Premature studies →

Lead sponsor

Sohag University is the lead sponsor of 1,230 studies on the registry; 636 are open to participants now.

Browse Sohag University studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All participants will receive short-term tocolytic therapy according to the unit protocol.

  • The choice of tocolytic agent (., Magnesium sulphate ) will be determined by the treating physician.
  • Tocolysis will be administered for a maximum duration of 48-72 hours.
  • Antenatal corticosteroids (Betamethasone amp 12mg once daily for 2days) will be administered to eligible participants to enhance fetal lung maturity.
  • Failure documented when there is efficient uterine contractions more 4/10mins each one lasts more than 40 seconds, and there was progressive cervical dilatation more 3cm

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age from 18 to 45 years old.
  • Singleton Pregnancy
  • Gestational age between 24 and 34 weeks, confirmed by last menstrual period and/or first-trimester ultrasound.
  • Diagnosis of preterm labor, defined as Regular uterine contractions (≥4 in 20 minutes recorded in CTG) with a documented change in cervical dilation (e.g., from\<1 cm to ≥2 cm) or, in nulliparous women, a dilation of ≥2 cm
  • Intact membranes at the time of presentation.

Exclusion criteria

Exclusion Criteria:

Established preterm labor (efficient uterine contractions 4/10mins each one lasts more than 40 Seconds recorded in CTG, with cervical changes (dilatation>4cm, effacement>80%)).

  • Evidence of chorioamnionitis or intrauterine infection.
  • Preterm premature rupture of membranes (PPROM).
  • Maternal medical disorders contraindicating tocolysis, such as severe preeclampsia, significant cardiac disease, or uncontrolled diabetes mellitus.
  • to continuation of pregnancy, including placental abruption or placenta previa with bleeding.
  • Vaginal bleeding of unknown origin" as a specific exclusion criterion, as it may indicate abruption or other pathologies.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Successful short-term tocolysis, defined as postponement of delivery for at least 48 hours after initiation of tocolytic therapy

    Time frame: 48 hours

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07696858
Lead sponsor
Sohag University
Responsible party
Mohamed Taleb Hussein Abdellattif (Mohamed Hussein Abdelatif Teleb, Sohag University) — Principal investigator
First posted
Jul 10, 2026
Start date
Aug 1, 2026 (estimated)
Primary completion
Jan 1, 2027 (estimated)
Completion
Jul 1, 2027 (estimated)
Last update
Jul 10, 2026

Study contacts

Mohamed Hussein Abdelatif Teleb Hussein Abdelatif Teleb, resident
Contact
mohamedhussein199819@gmail.com
01022475295

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Obstetric Labor, Premature →

Other studies from this sponsor

Sohag University →

Start the discussion